Keyphrases
Advanced Cancer
100%
Advanced Melanoma
11%
Adverse Events
33%
Anti-programmed Death 1
33%
Carcinoma
11%
Clinical Outcomes
11%
Clinically Meaningful Improvement
11%
Clinically Significant
11%
Cochrane Library
11%
Combination Therapy
11%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
33%
Data Extraction
11%
Data Synthesis
11%
Data Treatment
11%
Dermatitis
11%
Dichotomous Data
11%
EBSCO
11%
Embase
11%
Endocrine Disorders
11%
Gastrointestinal Toxicity
11%
Glioblastoma multiforme
11%
Hazard Ratio
33%
Hepatotoxicity
11%
Information Services
11%
Inverse-variance Weights
11%
Ipilimumab
11%
Kaplan-Meier Curve
11%
Log Hazard Ratio
11%
Malignant Pleural Mesothelioma
11%
Mantel-Haenszel Method
11%
Median Overall Survival
11%
Melanoma
100%
Meta-analysis
100%
Monotherapy
44%
Net Effect
11%
Nivolumab
100%
Nivolumab Plus Ipilimumab
100%
Non-associated
11%
Non-melanoma
11%
Non-small Cell Lung Cancer (NSCLC)
11%
Odds Ratio
11%
Outcome Estimation
11%
Overall Survival
44%
Patients with Advanced Cancer
11%
Pneumonitis
11%
Pooled Odds Ratios
33%
Programmed Death-ligand 1 (PD-L1)
11%
Progression-free Survival
55%
PubMed
11%
Sarcoma
11%
Selection Criteria
11%
Small Cell Lung Cancer
11%
Squamous Cell Lung Cancer
11%
Statistical Significance
11%
Summative Analysis
11%
Survival Outcomes
11%
Toxic Effects
11%
Treatment-related
44%
Urothelial Carcinoma
11%
Medicine and Dentistry
Advanced Cancer
100%
Adverse Event
18%
Carcinoma
6%
Combination Therapy
12%
Connective Tissue Cancer
6%
Cytotoxic T-Cell
18%
Dermatitis
6%
Endocrine Disease
6%
Gastrointestinal Toxicity
6%
Glioblastoma
6%
Hazard Ratio
25%
Ipilimumab
100%
Kaplan Meier Method
6%
Liver Toxicity
6%
Malignant Neoplasm
6%
Mantel Haenszel Test
6%
Melanoma
100%
Meta-Analysis
100%
Monotherapy
25%
Nivolumab
100%
Non Small Cell Lung Cancer
6%
Odds Ratio
25%
Overall Survival
31%
Pleura Mesothelioma
6%
Pneumonia
6%
Programmed Death 1 Ligand 1
6%
Progression Free Survival
31%
Small Cell Lung Cancer
6%
Squamous Cell Lung Carcinoma
6%
Toxicity
6%
Transitional Cell Carcinoma
6%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Adverse Event
18%
Carcinoma
6%
Combination Therapy
12%
Connective Tissue Cancer
6%
Dermatitis
6%
Endocrine Disease
6%
Gastrointestinal Toxicity
6%
Glioblastoma
6%
Hepatotoxicity
6%
Ipilimumab
100%
Malignant Neoplasm
6%
Melanoma
100%
Monotherapy
25%
Nivolumab
100%
Non Small Cell Lung Cancer
6%
Overall Survival
31%
Pleura Mesothelioma
6%
Pneumonia
6%
Programmed Death 1 Ligand 1
6%
Progression Free Survival
31%
Small Cell Lung Cancer
6%
Squamous Cell Lung Carcinoma
6%
Toxicity
6%
Transitional Cell Carcinoma
6%